Table 4. The characteristics of antimicrobial treatment for invasive non-typhoidal Salmonella patients.
| Antimicrobial prescribed | Count | Treatment, days | FCT, days a | ||
|---|---|---|---|---|---|
| n/Total (%) | n | Median (IQR) | n | Median (IQR) | |
| Any | 100/102 (98) | 98 | 7 (3–10) | 51 | 3 (2–8) |
| Ceftriaxone | 89/100 (89) | 89 | 7 (4–10) | 47 | 3 (2–7) |
| Monotherapy | 34/100 (34) | ||||
| Combination | 55/100 (55) | ||||
| Fluoroquinolone | 22/100 (22) | 22 | 10 (7–14) | 11 | 5 (2–10) |
| Monotherapy | 7/100 (7) | ||||
| Combination | 15/100(15) | ||||
| Combination therapy | 53/100 (53) | ||||
| CRO-FLQ | 16/100 (16) | 15 | 10 (7–12) | 9 | 4 (2–5) |
| CRO-SXT | 25/100 (25) | 25 | 6 (2–10) | 6 | 2 (2–5) |
| Other | 12/100 (12) | ||||
| Switched to a broader spectrum | 4/101 (4) | ||||
FCT: fever clearance time;
a) non-fatal cases only;
CRO-FLQ: ceftriaxone-fluoroquinolone; CRO-SXT: ceftriaxone- trimethoprim-sulfamethoxazole